Cincinnati, OH, United States
Cincinnati, OH, United States

Time filter

Source Type

"NCCN Foundation is proud to support this important resource which indeed will empower patients with thyroid cancer and their caregivers to make informed choices about their care," said Marcie R. Reeder, MPH, Executive Director, NCCN Foundation. "We are incredibly grateful for the generous support from our sponsors, ThyCa and Rockin' for the Cure, as their sponsorship for these resources gives patients access to the same treatment information that their doctors use." "Thyroid Cancer is challenging because it affects people of all ages from young children through seniors, is especially life-disrupting and stressful when diagnosed in younger patients, and needs lifelong monitoring and management even in low-risk patients," said Gary Bloom, ThyCa Executive Director, and Thyroid Cancer survivor of 21 years. "ThyCa is very pleased to support these important guidelines, which will be helpful resources for both patients and their caregivers." NCCN Guidelines for Patients are easy-to-understand adaptations based on the same clinical practice guidelines used by health care professionals around the world to determine the best way to treat a person with cancer. Each resource features unbiased expert guidance from the nation's leading cancer centers designed to help people living with cancer understand and discuss their treatment options with their providers. NCCN Guidelines for Patients and NCCN Quick Guide™ sheets—one-page summaries of key points in the patient guidelines—are written in plain language and include patient-friendly tools, such as questions to ask your doctor, a glossary of terms, and medical illustrations of anatomy, tests, and treatment.  NCCN Guidelines for Patients and NCCN Quick Guide™ sheets DO NOT replace the expertise and clinical judgment of the clinician. NCCN currently offers NCCN Guidelines for Patients for the following: Brain, Breast, Colon Distress, Esophageal, Kidney, Non-Small Cell Lung, Ovarian, Pancreatic, Prostate, Stomach, and Thyroid Cancers; Acute Lymphoblastic Leukemia; Adolescents and Young Adults with Cancer; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Hodgkin Lymphoma; Lung Cancer Screening; Malignant Pleural Mesothelioma; Melanoma; Multiple Myeloma; Myelodysplastic Syndromes; Nausea and Vomiting; Non-Hodgkin's Lymphomas; Soft Tissue Sarcoma; and Waldenström's Macroglobulinemia. The NCCN Guidelines for Patients and NCCN Quick Guide™ sheet for Thyroid Cancer are available to download for free at NCCN.org/patients and on the NCCN Patient Guides for Cancer mobile app. NCCN Foundation® was founded by the National Comprehensive Cancer Network® (NCCN®) to empower people with cancer and advance oncology innovation. NCCN Foundation supports people with cancer and their caregivers at every step of their treatment journey by delivering unbiased expert guidance from the world's leading cancer experts through the library of NCCN Guidelines for Patients® and other patient education resources. NCCN Foundation is also committed to advancing cancer treatment by funding the nation's promising young investigators at the forefront of cancer research, initiating momentum in their careers and furthering the betterment of patients through their groundbreaking innovations. For more information about NCCN Foundation, visit NCCNFoundation.org. ThyCa: Thyroid Cancer Survivors' Association, Inc., an international nonprofit organization founded in 1995 and advised by thyroid cancer specialists, educates and supports patients and families through its website, online and face-to-face support groups, one-to-one support, over 50 videos with experts on its YouTube Channel, handbooks on all thyroid cancer types, downloadable low-iodine cookbook, online newsletter, and materials in 10 languages. ThyCa sponsors seminars, workshops, and the annual International Thyroid Cancer Survivors' Conference, as well as Thyroid Cancer Awareness Month, year-round awareness programs for early detection, and thyroid cancer research funds and research grants. For more information visit http://www.thyca.org. About the National Comprehensive Cancer Network The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The NCCN Member Institutions are: Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT. [1] Robert I. Haddad, MD, et. al., NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma, Version 1.2017. © 2017 National Comprehensive Cancer Network, Inc.  Available at NCCN.org. Accessed: May 8, 2017 [2] "Cancer Stat Facts: Thyroid Cancer." Surveillance, Epidemiology, and End Results Program. National Cancer Institute, n.d. Web. 08 May 2017. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nccn-publishes-new-patient-education-resources-for-thyroid-cancer----one-of-the-most-commonly-diagnosed-cancers-in-women-in-the-united-states-300456776.html


The study, "Are We on the Same Page? Patient and Provider Perceptions about Exercise in Cancer Care: A Focus Group Study," published in the May 2017 issue of JNCCN – Journal of the National Comprehensive Cancer Network is available free of charge on JNCCN.org until July 30, 2017. "Our results indicate that exercise is perceived as important to patients with cancer, both from a patient and physician perspective; however, physicians are reluctant to consistently include PA recommendations in their patient discussions. Our findings highlight the value of examining both patient and provider attitudes and behavioral intentions," said Dr. Smaradottir. "While we uncovered barriers to exercise recommendations, questions remain on how to bridge the gap between patient and provider preferences." Where they exercise is important to patients. More than 80% of those surveyed noted that they would prefer a home-based exercise regimen that could be performed in alignment with their personal schedules and symptoms. Patients also noted a preference that exercise recommendations come from their oncologists, as they have an established relationship and feel that their oncologists best understand the complexities of their personalized treatment plans. Although patients prefer PA at home, Dr. Smaradottir found that practitioners wish to refer patients to specialist care for exercise recommendations. The practitioners surveyed noted not only mounting clinic schedules, but also a lack of education about appropriate PA recommendations for patients. Furthermore, they expressed concern about asking patients to be more physically active during chemotherapy and radiation, and also expressed trepidation about prescribing PA to frail patients with limited mobility. "We were surprised by the gap in expectations regarding exercise recommendation between patients and providers. Many providers, ourselves included, thought patients would prefer to be referred to an exercise center, but they clearly preferred to have a home based program recommended by their oncologist," Dr. Smaradottir said. Exercise was felt to be an equally important part of treatment and well-being for patients with early stage cancer treated with curative intent as well as patients receiving palliative therapy. For the focus groups, the investigators interviewed 20 patients aged 45 and older – 10 with stage I-III non-metastatic cancer after adjuvant therapy and 10 with stage IV metastatic disease undergoing palliative treatment, both across multiple tumor types. Additionally, the researchers interviewed nine practitioners.  The authors note that while the sample size is limited, because the subjects of the study all hailed from the same institution, the study provides an understanding of how the group as a whole has the potential to influence the practice of PA recommendations. Smaradottir et al note that physician education is paramount and suggest that successful implementation of an education protocol should begin with a multidisciplinary collaboration between treating providers and physical therapy specialists, exercise physiologists, and other sub specialties. They add that the emphasis of such a program should be on a patient-centered approach, making the recommendations specific for each patient. "Indeed, physicians, fellows, and residents who collaborate with a PA specialist through a shared-care clinic visit will gain valuable education about how to discuss exercise recommendations with their patients," said Dr. Smaradottir. Currently, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship recommend exercise for cancer survivors. "Physical activity is emerging as an important adjunct therapy in the treatment of multiple cancers, and there is consensus that physical activity is helpful to patients with cancer and survivors in terms of augmenting symptom burden and maintaining overall health. This study highlights the discord between what we think is important and what we do in actual practice as providers. It also highlights patients' desire to remain physically active and to receive guidance from their oncologists regarding what they can and should be doing. Based on the results of this and other studies, further work on both defining what the optimal physical activity recommendation for patients should be and determining how best to train our oncologic workforce to implement recommendations is needed," said Crystal Denlinger, MD, Chief of Gastrointestinal Medical Oncology and Associate Professor, Department of Hematology/Oncology at Fox Chase Cancer Center, and Chair of the NCCN Guidelines® Panel for Survivorship. Free access to this article is available until July 30, 2017, on JNCCN.org. About JNCCN – Journal of the National Comprehensive Cancer Network More than 24,000 oncologists and other cancer care professionals across the United States read JNCCN–Journal of the National Comprehensive Cancer Network. This peer-reviewed, indexed medical journal provides the latest information about best clinical practices, health services research, and translational medicine. JNCCN features updates on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), review articles elaborating on guidelines recommendations, health services research, and case reports highlighting molecular insights in patient care. JNCCN is published by Harborside Press. Visit JNCCN.org. To inquire if you are eligible for a FREE subscription to JNCCN, visit http://www.nccn.org/jnccn/subscribe.asp JNCCN 360 is a new online resource for oncology professionals featuring up-to-date news, literature, trials, clinical perspectives on current therapies, and much more. Visit JNCCN360.org About the National Comprehensive Cancer Network The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The NCCN Member Institutions are: Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/despite-evidence-that-it-benefits-patients-with-cancer-study-finds-most-oncologists-dont-discuss-exercise-with-patients-300456186.html


News Article | May 18, 2017
Site: www.biosciencetechnology.com

Of the quarter-million women diagnosed with breast cancer every year in the United States, about 180,000 undergo surgery to remove the cancerous tissue while preserving as much healthy breast tissue as possible. However, there’s no accurate method to tell during surgery whether all of the cancerous tissue has been successfully removed. The gold-standard analysis takes a day or more, much too long for a surgeon to wait before wrapping up an operation. As a result, about a quarter of women who undergo lumpectomies receive word later that they will need a second surgery because a portion of the tumor was left behind. Now, researchers at Washington University School of Medicine in St. Louis and California Institute of Technology report that they have developed a technology to scan a tumor sample and produce images detailed and accurate enough to be used to check whether a tumor has been completely removed. Called photoacoustic imaging, the new technology takes less time than standard analysis techniques. But more work is needed before it is fast enough to be used during an operation. The research is published May 17 in Science Advances. “This is a proof of concept that we can use photoacoustic imaging on breast tissue and get images that look similar to traditional staining methods without any sort of tissue processing,” said Deborah Novack, M.D., Ph.D., an associate professor of medicine, and of pathology and immunology, and a co-senior author on the study. The researchers are working on improvements that they expect will bring the time needed to scan a specimen down to 10 minutes, fast enough to be used during an operation. The current gold-standard method of analysis, which is based on preserving the tissue and then staining it to make the cells easier to see, hasn’t gotten any faster since it was first developed in the mid-20th century. For solid tumors in most parts of the body, doctors use a technique known as a frozen section to do a quick check of the excised lump during the surgery. They look for a thin rim of normal cells around the tumor. Malignant cells at the margins suggest the surgeon missed some of the tumor, increasing the chances that the disease will recur. But frozen sections don’t work well on fatty specimens like those from the breast, so the surgeon must finish a breast lumpectomy without knowing for sure how successful it was. “Right now, we don’t have a good method to assess margins during breast cancer surgeries,” said Rebecca Aft, M.D., Ph.D., a professor of surgery and a co-senior author on the study.  Aft, a breast cancer surgeon, treats patients at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine. Currently, after surgery a specimen is sent to a pathologist, who slices it, stains it and inspects the margins for malignant cells under a microscope. Results are sent back to the surgeon within a few days. To speed up the process, the researchers took advantage of a phenomenon known as the photoacoustic effect. When a beam of light of the right wavelength hits a molecule, some of the energy is absorbed and then released as sound in the ultrasound range. These sound waves can be detected and used to create an image. “All molecules absorb light at some wavelength,” said co-senior author Lihong Wang, PhD, who conducted the work when he was a professor of biomedical engineering at Washington University’s School of Engineering & Applied Science. He is now at Caltech. “This is what makes photoacoustic imaging so powerful. Essentially, you can see any molecule, provided you have the ability to produce light of any wavelength. None of the other imaging technologies can do that. Ultrasound will not do that. X-rays will not do that. Light is the only tool that allows us to provide biochemical information.” The researchers tested their technique by scanning slices of tumors removed from three breast cancer patients. For comparison, they also stained each specimen according to standard procedures. The photoacoustic image matched the stained samples in all key features. The architecture of the tissue and subcellular detail such as the size of nuclei were clearly visible. “It’s the pattern of cells – their growth pattern, their size, their relationship to one another – that tells us if this is normal tissue or something malignant,” Novack said. “Overall, the photoacoustic images had a lot of the same features that we see with standard staining, which means we can use the same criteria to interpret the photoacoustic imaging. We don’t have to come up with new criteria.” Having established that photoacoustic techniques can produce usable images, the researchers are working on reducing the scanning time. “We expect to be able to speed up the process,” Wang said. “For this study, we had only a single channel for emitting light. If you have multiple channels, you can scan in parallel and that reduces the imaging time. Another way to speed it up is to fire the laser faster. Each laser pulse gives you one data point. Faster pulsing means faster data collection.” Aft, Novack and Wang are applying for a grant to build a photoacoustic imaging machine with multiple channels and fast lasers. “One day we think we’ll be able to take a specimen straight from the patient, plop it into the machine in the operating room and know in minutes whether we’ve gotten all the tumor out or not,” Aft said. “That’s the goal.”

Loading Jewish Hospital collaborators
Loading Jewish Hospital collaborators